- $56.06m
- $38.98m
- $0.03m
U.S. STOCKS ON THE MOVE-Alphabet, Boeing, Tesla
Brief: AcelRx Pharmaceuticals Announces Presentation Of Investigator-Initiated Trial Results
U.S. STOCKS ON THE MOVE-Skechers, Spotify, Twitter
AcelRx Pharma drops on reverse stock split plan
Brief: AcelRx Pharmaceuticals Announces Reverse Stock Split
Brief: AcelRx Pharmaceuticals Announces Anesthesiology 2022 Annual Meeting Presentation On Dsuvia For Battlefield Analgesia By The Uniformed Services University Of The Health Sciences
AcelRx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Acelrx Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Corporate Update
Brief: AcelRx Pharmaceuticals Announces Abstract Acceptance For Podium Presentation At The Anesthesiology 2022 Annual Meeting
AcelRx Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA
AcelRx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Acelrx Pharmaceuticals Reports First Quarter 2022 Financial Results And Provides Corporate Update
Preview: AcelRx Pharmaceuticals gains ahead of Q1 results
AcelRx Pharmaceuticals Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: AcelRx Pharmaceuticals Announces Publication Of Results From An Investigator-Initiated Trial On Sufentanil Sublingual Tablet (SST) Compared To Standard Intravenous Opioids During Plastic Surgery Procedures Performed Under General Anesthesia
Brief: AcelRx Pharmaceuticals Received Nasdaq Notice Of Non-Compliance With Market Value Of Listed Securities Requirement
Brief: Acelrx Pharmaceuticals Files Prospectus Relates To Proposed Resale From Time To Time By Selling Stockholders Of Up To 11.02 Million Shares
Brief: AcelRx Pharma Says Received Close-Out Letter From OPDP Indicating FDA Concluded Its Evaluation Of Co's Corrective Actions In Response To Warning Letter